Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Current issues in reperfusion therapy

B J Gersh1

  • 1Division of Cardiology, Georgetown University Medical Center, Washington, DC 20007-2197, USA.

The American Journal of Cardiology
|November 11, 1998
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Influence of albuminuria on cardiovascular risk in patients with stable coronary artery disease. Circulation 116: 2687-2693, 2007.

Clinical journal of the American Society of Nephrology : CJASN·2023
Same author

Cardiac troponin is associated with cardiac outcomes in men and women with atrial fibrillation, insights from the ARISTOTLE trial.

Journal of internal medicine·2020
Same author

Effect of Low-Dose Rapamycin on Senescence Markers and Physical Functioning in Older Adults with Coronary Artery Disease: Results of a Pilot Study.

The Journal of frailty & aging·2016
Same author

D-dimer and risk of thromboembolic and bleeding events in patients with atrial fibrillation--observations from the ARISTOTLE trial.

Journal of thrombosis and haemostasis : JTH·2014
Same author

Diabetes, incretin hormones and cardioprotection.

Heart (British Cardiac Society)·2014
Same author

The prognostic implications of lack of palpitations in patients hospitalised with atrial fibrillation: observations from a 20-year registry.

International journal of clinical practice·2013
Same journal

Real-World Effectiveness and Tolerability of Sacubitril/Valsartan in Octogenarian Patients With Heart Failure: Results From the PARACHUTER Study.

The American journal of cardiology·2026
Same journal

ECG-Guided Conduction Pathways as a Lever to Shorten Post-TAVI Hospitalization.

The American journal of cardiology·2026
Same journal

Cystatin-C versus creatinine and kidney function in heart failure with preserved ejection fraction: a SOGALDI-PEF analysis.

The American journal of cardiology·2026
Same journal

Balloon-expandable versus Self-expanding Valves in Patients with Small Aortic Annuli Undergoing Transcatheter Aortic Valve Replacement.

The American journal of cardiology·2026
Same journal

Drug-Coated Balloons versus Drug-Eluting Stents following Coronary Atherectomy in Severely Calcified Lesions: A Systematic Review and Meta-Analysis.

The American journal of cardiology·2026
Same journal

Prehospital Statin Therapy and Outcomes in ST-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.

The American journal of cardiology·2026
See all related articles

Reperfusion therapies like thrombolytics and primary angioplasty are crucial for myocardial infarction management. While effective, research continues to improve outcomes and speed of reperfusion for better patient survival.

Area of Science:

  • Cardiology
  • Vascular Medicine
  • Interventional Cardiology

Background:

  • Thrombosis is the primary cause of myocardial infarction (MI).
  • Reperfusion therapies, including thrombolytics and primary angioplasty, are central to acute coronary syndrome management.
  • Intravenous thrombolytic therapy has demonstrated mortality benefits in MI patients.

Purpose of the Study:

  • To review the evolution and efficacy of reperfusion therapies for acute myocardial infarction.
  • To compare the effectiveness of thrombolytics versus primary angioplasty in achieving reperfusion and improving outcomes.
  • To identify limitations and future research directions for improving reperfusion strategies.

Main Methods:

  • Review of large randomized trials and clinical data on reperfusion therapies.

Related Experiment Videos

  • Analysis of outcomes related to thrombolytic agents (e.g., tPA) and percutaneous transluminal coronary angioplasty (PTCA).
  • Evaluation of factors influencing reperfusion success, such as time to treatment and Thrombolysis in Myocardial Infarction (TIMI) grade 3 flow.

    • Main Results:

    • Intravenous thrombolytics, particularly tPA with heparin, reduce mortality but achieve optimal reperfusion (TIMI grade 3 flow) in only ~55% of patients.
    • PTCA offers higher rates of TIMI grade 3 flow and lower reocclusion but shows institutional variability and inconsistent 6-month benefits.
    • Limitations include reocclusion, cellular damage, and microvascular dysfunction impacting thrombolytic efficacy.

    Conclusions:

    • Both thrombolytics and PTCA play vital roles in MI reperfusion, each with distinct advantages and limitations.
    • Achieving rapid and complete reperfusion (TIMI grade 3 flow) is critical for improving patient outcomes.
    • Further research into novel thrombolytics, angioplasty techniques, stents, and antithrombotics is needed to enhance reperfusion rates and speed.